23 Jul, 2026
According to Straits Research, the global blood preparation market size was valued at $52.97 billion in 2025 and is projected to grow from $56.07 billion in 2026 to $88.35 billion by 2034, registering a CAGR of 5.85% during the forecast period 2026–2034.
The global blood preparation market is experiencing significant growth, largely due to the increasing prevalence of chronic illnesses such as cancer, anemia, hemophilia, and cardiovascular diseases. These conditions drive the demand for various blood components, including plasma, platelets, and red blood cells. The aging global population further supports this trend, as elderly individuals are more prone to health issues requiring regular transfusions or anticoagulant treatments.
In addition, government-led initiatives and public awareness campaigns promoting blood donation and ensuring transfusion safety have played a crucial role in improving access to blood products and encouraging community participation. The market is also benefiting from the expanding infrastructure of blood banks and collection centers, particularly in developing regions, which is improving the availability and distribution of blood supplies. Moreover, heightened awareness about the need for early detection and treatment of blood disorders is boosting the demand for advanced blood preparation and storage solutions. Collectively, these factors are propelling the growth of the global blood preparation market.
The increasing prevalence of surgical interventions and trauma incidents worldwide serves as a major catalyst for the growth of the blood preparation market. Advancements in medical technologies and the expansion of healthcare facilities—especially in developing nations—are contributing to a steady rise in the number of surgeries performed. Blood components such as red blood cells, plasma, and platelets play a vital role in managing blood loss and supporting patient recovery during surgical and emergency care.
This increasing need for surgical and trauma care is expected to significantly fuel the demand for blood preparation products, thereby propelling market expansion in the near future.
The growing emphasis on rare blood disorders is creating substantial growth potential for the global blood preparation market. Conditions like paroxysmal nocturnal hemoglobinuria (PNH), sickle cell anemia, and hemophilia are gaining increased focus from pharmaceutical firms and research organizations. This surge is fueled by progress in genomics and biotechnology, which are driving the development of more precise and effective treatment options.
This drive toward innovative therapies for rare blood diseases is anticipated to broaden treatment choices and stimulate further investments in blood preparation technologies.
The North American blood preparation market is experiencing significant growth driven by advanced healthcare infrastructure and increased funding for blood safety initiatives. The U.S. leads with widespread adoption of innovative blood processing technologies such as pathogen reduction systems like Cerus Corporation’s INTERCEPT Blood System, enhancing transfusion safety. Additionally, rising cases of chronic diseases, including cancer and hemophilia, contribute to growing demand for plasma-derived products and coagulation factors.
Furthermore, the presence of prominent blood banks like the American Red Cross and enhanced regulatory frameworks by the FDA ensure high standards in blood collection and preparation. Moreover, expansion in outpatient surgical procedures and increasing use of personalized blood therapies support market growth. Investments in digital platforms for efficient blood inventory management, exemplified by the use of AI-based donor matching systems, are improving supply chain efficiency. The region’s focus on research into synthetic blood and rare blood disorders also opens new avenues for innovation and market expansion.
sales@straitsresearch.com